Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
Retatrutide reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
Retatrutide is a synthetic peptide conjugated to a fatty diacid moiety; gip/glp-1/glucagon triple receptor agonist. Structurally engineered around an oxyntomodulin backbone.
A single peptide chain conjugated to a fatty diacid. It is the first triple agonist to reach Phase 3 trials for obesity.
Reported to activate GIP, GLP-1 and glucagon receptors simultaneously. Vectra makes no claim as to mechanism or effect.
An investigational molecule still in clinical development. Trial data belongs to its sponsor and is not reproduced here.
Studied in incretin and glucagon receptor pharmacology. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
Investigational and not approved in any jurisdiction. No efficacy or safety conclusion can be drawn from this catalog, and the sponsor's trial data is not reproduced here.
Our sources carry no CAS number, formula, molecular weight, sequence, or storage data for Retatrutide.
Not approved by FDA, EMA, PMDA, NMPA or MFDS. It cannot legally be compounded: it fails all three 503A/503B criteria — no USP/NF monograph, not a component of an approved drug, not on the shortage list. The Alliance for Pharmacy Compounding has warned members not to compound it. Direct-to-consumer sale of an unapproved investigational drug is unlawful under the FD&C Act. No therapeutic, preventive, or diagnostic claims are made or implied.
Yes — in more than one way:
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.
Compatibility does not assert current availability. No preparation, ratio, or protocol guidance renders here.